

## Aminocardiolipin

Catalog number: L-C16A Molecular Formula:  $C_{69}H_{135}NO_{17}P_2$ MW: 1312.75 CAS#: n/a

**Solubility:** *t*-BuOH/water 1:1 (v/v), CHCl<sub>3</sub>, CH<sub>3</sub>OH. Concentrations >1 mg/mL may require sonication and gentle heating.

**Storage and Handling:** Aminocardiolipin (ACL) is stable for at least one year when stored as a solid, protected from moisture, and light at -20°C. Reconstitute with the solvent of choice, dilute with water or neutral pH, buffered salt solutions as needed. <u>NOTE: if the product is intended for use with amine-reactive surfaces/substrates, primary/secondary amine containing buffers (e.g. TRIS) cannot be used.</u> Should be stored in glass containers to prevent material loss due to adsorption to the vessel surface. Storage in basic (pH > 9) or acidic (pH < 4) buffers will result in slow decomposition of the product. After reconstitution, solutions of ACL should be stored at -20°C between uses.

**Background:** Cardiolipin (CL) is an important component in prokaryotic and in eukaryotic inner mitochondrial membrane.<sup>1</sup> In humans, CL is made by cardiolipin synthase from phosphatidylglycerol and cytidinediphosphatediacylglycerol.<sup>2</sup> Due to its four acyl chains and small head group, CL can organize into domains which can be proton sinks, fill cavities at protein interfaces, stabilize protein oligomers, and participate in high-curvature membrane regions. Autoantibodies to CL have been found in patients with anti-phospholipid syndrome and lupus<sup>3</sup>. ACL is a synthetic analog of CL with 12-aminododecanoic acid allowing for lipid modification with reporter groups and immobilization on amine-reactive surfaces.

**References:** 1. Schlame M, Horvath L, Vigh L. Relationship between lipid saturation and lipid-protein interaction in liver mitochondria modified by catalytic hydrogenation with reference to cardiolipin molecular species. Biochem J 1990;265:79-85.

2. Houtkooper RH, Vaz FM. Cardiolipin, the heart of mitochondrial metabolism. Cell Mol Life Sci 2008;65:2493-506.

3. Xu Y, Malhotra A, Ren M, Schlame M. The enzymatic function of tafazzin. J Biol Chem 2006;281:39217-24.

Hazardous Properties and Cautions: The toxicological and pharmacological properties of this compound are not fully known. For further information see the MSDS on request. This product is manufactured and shipped only in small quantities, intended for research and development in a laboratory utilizing prudent procedures for handling chemicals of unknown toxicity, under the supervision of persons technically qualified to evaluate potential risks and authorized to enforce appropriate health and safety measures. As with all research chemicals, precautions should be taken to avoid unnecessary exposures or risks.

Warranty and Disclaimer: Echelon warrants the product conforms to the specifications stated herein. In the event of nonconformity, Echelon will replace products or refund purchase price, at its sole option, and Echelon shall not be responsible for any other loss or damage, whether known or foreseeable to Echelon. No other warranties apply, express or implied, including but not limited to warranty of fitness for any purpose or implied warranty of merchantability. Purchaser is solely responsible for all consequences of its use of the product and Echelon assumes no responsibility therefore, including success of purchaser's research and development, or health or safety of any uses of the product.

Technical Data Sheet, Rev 2, 6/27/2024 - For research use only. Not intended for diagnostic or therapeutic use.



Ph: 866-588-0455

Fax: 801-588-0497